Precision NanoSystems Inc. (PNI) is a global leader in ushering in the next wave of genomic medicines in infectious diseases, cancer, and rare diseases. We work with the world’s leading drug developers to understand disease and create the therapeutics and vaccines that will define the future of medicine.
PNI’s NanoAssemblr® microfluidic instruments, GenVoy™ lipid nanoparticle delivery reagents, and Biopharmaceutical Services enable researchers to translate disease biology insights into nonviral genomic medicines.
Charles River Laboratories
Only 0.01% of drug candidates entering clinical trials reach the market. With Charles River supporting >80% of drugs approved by the FDA over the last three years, improve your odds, leverage our experience, and expedite your time to market.
Our comprehensive portfolio supporting proteins, antibodies, vaccines, and cell and gene therapies includes:
- C> CDMO Solutions
- Cell Bank, Virus Manufacturing
- Biophysical, Molecular, Genetic Characterization Services
- Biosafety, Viral Clearance Studies
- Bioactivity, Potency Testing
- Stability, QC Testing
BIA Separations, recently acquired by Sartorius, offers solutions for purification and analysis of large biomolecules, such as viruses, plasmids and mRNA, which are applied in cell and gene therapies.
BIA develops and manufactures market-leading CIM® monolithic chromatographic columns and provides superior research and method development services for their customers. BIA’s technology for manufacturing scale purification is already used in production of the first commercialized advanced therapeutics; BIA also has a keen presence with novel drug candidates in the clinical pipeline.
Cytiva is a global life sciences leader dedicated to advancing and accelerating therapeutics. Cytiva is a trusted partner to customers that undertake lifesaving activities ranging from biological research to developing innovative vaccines, biologic drugs, and novel cell and gene therapies. Cytiva brings speed, efficiency and capacity to research and manufacturing workflows, enabling the development, manufacture and delivery of transformative medicines to patients.
VGXI, Inc. is a leading contract manufacturer of DNA-based pharmaceuticals with nearly 20
years of experience providing high quality cGMP products to clinical trials worldwide. Uses include DNA vaccines, immunotherapies, and cell and gene therapy applications. The company’s continuous, lowshear AIRMIX® lysis technology and optimized purification process provide highly supercoiled plasmid material at concentrations as high as 15 mg/ ml while maintaining exceptional purity and DNA quality. Pre-Clinical through GMP RNA manufacturing services are also available.